Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

President Trump has touted apprenticeships as part of his promise of a golden era for American workers. But are his ...